A University of Dundee spin-out has formed a new company dedicated to developing new obesity therapies that avoid the muscle ...

Lizzo has shown off her dramatic weight loss in a new Instagram before-and-after post - and fans are all saying the same ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

For people who constantly think about what they are going to eat meal to meal, their food noise goes down significantly’ ...

Medications known as GLP-1 inhibitors have made headlines in recent years due to their effectiveness in managing blood sugar ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.